Guggenheim Capital LLC Sells 14,905 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Guggenheim Capital LLC lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 26.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 41,461 shares of the biopharmaceutical company's stock after selling 14,905 shares during the period. Guggenheim Capital LLC's holdings in TG Therapeutics were worth $1,248,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in TGTX. XTX Topco Ltd bought a new position in TG Therapeutics during the 4th quarter worth $400,000. Summit Investment Advisors Inc. increased its position in TG Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after acquiring an additional 463 shares during the period. Raymond James Financial Inc. acquired a new stake in TG Therapeutics in the 4th quarter worth about $14,508,000. Advisory Services Network LLC boosted its holdings in TG Therapeutics by 19.5% in the 4th quarter. Advisory Services Network LLC now owns 10,359 shares of the biopharmaceutical company's stock valued at $312,000 after purchasing an additional 1,693 shares during the period. Finally, Invesco Ltd. grew its position in shares of TG Therapeutics by 1.2% during the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock worth $27,985,000 after purchasing an additional 10,989 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Price Performance

Shares of TGTX traded up $1.03 during trading hours on Friday, reaching $41.33. The stock had a trading volume of 1,464,365 shares, compared to its average volume of 3,088,224. The stock has a market capitalization of $6.56 billion, a PE ratio of -413.26 and a beta of 2.14. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company's 50-day moving average is $36.98 and its two-hundred day moving average is $32.31.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. Research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.